コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ., attention deficit hyperactivity disorder, drug addiction).
2 acetylcholine, serotonin, and dopamine) and drug addiction.
3 iated with compulsive obsessive disorder and drug addiction.
4 animals toward risky options and facilitate drug addiction.
5 athological conditions, such as gambling and drug addiction.
6 include generalized anxiety, depression, and drug addiction.
7 Ca2 channels (KCNN1-3) influence alcohol and drug addiction.
8 t process for candidate medications to treat drug addiction.
9 regions of genes that have pivotal roles in drug addiction.
10 numerous societal problems, from obesity to drug addiction.
11 , RPE signaling is thought to be impaired in drug addiction.
12 that the actions of dopamine are critical to drug addiction.
13 relapses that are common in adolescent-onset drug addiction.
14 implicated in neurodegenerative disease and drug addiction.
15 lasticity, which is involved in learning and drug addiction.
16 as posttraumatic stress disorder (PTSD) and drug addiction.
17 implicated in neurodegenerative disease and drug addiction.
18 been associated with different dimensions of drug addiction.
19 new therapeutic avenue for the treatment of drug addiction.
20 pulsivity as key psychological constructs in drug addiction.
21 the pharmacogenetic treatment of alcohol and drug addiction.
22 europsychiatric disorders including PTSD and drug addiction.
23 reward processing and motivated behavior in drug addiction.
24 fy the efficacy of maintenance treatments in drug addiction.
25 not been explicitly tested in the context of drug addiction.
26 ting other neurological disorders, including drug addiction.
27 nduced drug relapse, a major factor in human drug addiction.
28 stress reactivity are central components in drug addiction.
29 tors of neuropsychiatric diseases, including drug addiction.
30 ortant in the development and persistence of drug addiction.
31 ications in reward memory and development of drug addiction.
32 rs such as posttraumatic stress disorder and drug addiction.
33 tosensory system functional development, and drug addiction.
34 biomarkers and novel therapeutic targets for drug addiction.
35 the modulation of mood disorders as well as drug addiction.
36 to advance cannabinoid-based treatments for drug addiction.
37 peutics for psychiatric disorders, including drug addiction.
38 tric disorders such as Parkinson disease and drug addiction.
39 vention of dysfunctional DA transmission and drug addiction.
40 lso inform the development of treatments for drug addiction.
41 long-term synaptic plasticity, learning, and drug addiction.
42 investigated in animal and human research on drug addiction.
43 pathophysiology of complex disorders such as drug addiction.
44 s a role in L-dopa-induced dyskinesia and in drug addiction.
45 ch as autism, schizophrenia, Alzheimer's and drug addiction.
46 tensive health complications associated with drug addiction.
47 lie several psychiatric disorders, including drug addiction.
48 including maladaptive responses involved in drug addiction.
49 ar mechanisms controlling mood disorders and drug addiction.
50 o, Parkinson disease, anxiety disorders, and drug addiction.
51 is circuit might alter behaviours related to drug addiction.
52 ny diseases and psychopathologies, including drug addiction.
53 behavioral and neurobiological framework as drug addiction.
54 nt of astrocytes in human pathophysiology of drug addiction.
55 target toward treating pain, depression, and drug addiction.
56 ology of disorders such as schizophrenia and drug addiction.
57 the NAc as a promising therapeutic lever in drug addiction.
58 rovide new insights into the neurobiology of drug addiction.
59 buse is hypothesized to increase the risk of drug addiction.
60 sting OX1 antagonism could be therapeutic in drug addiction.
61 iological processes including locomotion and drug addiction.
62 ent and relapse of drug-seeking behaviors in drug addiction.
63 prevention and treatment of both obesity and drug addiction.
64 vulnerability to relapse in rodent models of drug addiction.
65 ders including schizophrenia, depression and drug addiction.
66 such disorders as impulsivity, obesity, and drug addiction.
67 umans, paralleling the tolerance observed in drug addiction.
68 g neurocognitive endophenotype for stimulant drug addiction.
69 itivity, a known risk factor for alcohol and drug addiction.
70 rizes disorders ranging from binge eating to drug addiction.
71 ately identify new treatments for obesity or drug addiction.
72 l area (VTA) are involved at early phases of drug addiction.
73 s for epigenetic therapeutics in alcohol and drug addiction.
74 Immunotherapy is a promising treatment for drug addiction.
75 Hypocretin (orexin) signaling is involved in drug addiction.
76 aviors in the development of opioid-mediated drug addiction.
77 pioids, a potentially important mechanism in drug addiction.
78 contingent punishment is a core phenotype of drug addiction.
79 naptic plasticity, associative learning, and drug addiction.
80 ons into the epigenetic and genetic basis of drug addiction.
81 ophrenia, obsessive-compulsive disorder, and drug addiction.
82 echanisms may therefore underlie obesity and drug addiction.
83 een suggested, but never directly tested, in drug addiction.
84 ex (ACC) have been implicated in alcohol and drug addiction.
85 tex (ACC) has been implicated in alcohol and drug addiction.
86 rd-based conditioning and the development of drug addiction.
87 d has been linked with an increased risk for drug addiction.
88 g cognitive demand are a hallmark deficit in drug addiction.
89 ) neurons underlies a key pathophysiology of drug addiction.
90 e extensive knowledge of the neurobiology of drug addiction.
91 disorders such as post-traumatic stress and drug addiction.
92 that assess the factors that comprise female drug addiction.
93 is a key component of the pathophysiology of drug addiction.
94 a role for orexins in reward processing and drug addiction.
95 psychiatric disorders, including anxiety and drug addiction.
96 r example post-traumatic stress disorder and drug addiction.
97 administration environment are important in drug addiction.
98 may regulate plasticity processes underlying drug addiction.
99 amma localization in brain areas involved in drug addiction.
100 erbate neuropsychiatric disorders, including drug addiction.
101 king habits that are a key characteristic of drug addiction.
102 anisms mediating adolescent vulnerability to drug addiction.
103 ts into the genesis and neural mechanisms of drug addiction.
104 promising pharmacological approach to treat drug addiction.
105 id with neuropsychiatric diseases, including drug addiction.
106 ing behavioral adaptations that characterize drug addiction.
107 obiology of socially driven vulnerability to drug addiction.
108 n system is a potential treatment target for drug addiction.
109 to Parkinson disease, anxiety disorders, and drug addiction.
110 ious diseases including neuropathic pain and drug addiction.
111 h as schizophrenia, Parkinson's disease, and drug addiction.
112 lating impulsivity-related disorders such as drug addiction.
113 ng abstinence is a defining feature of human drug addiction.
114 interventions could be effective in treating drug addiction.
115 underpinnings for compulsive overeating and drug addiction.
116 attention-deficit hyperactivity disorder and drug addiction.
117 havioral processes related to motivation and drug addiction.
118 provide promising therapeutic approaches in drug addiction.
119 mate behaviors spanning anxiety behavior and drug addiction.
120 tagonism as a potential treatment option for drug addiction.
121 ehavioral and pharmacological treatments for drug addiction.
122 to impaired impulse control associated with drug addiction.
123 with language, autism spectrum disorder, and drug addiction.
124 al striatum (VS) as a possible treatment for drug addiction.
125 vel and effective therapeutic strategies for drug addiction.
126 embles the perceived loss of control seen in drug addiction.
127 nalling in the brain plays a central role in drug addiction.
128 entral to the development and maintenance of drug addiction.
129 se in treating neuropsychiatric diseases and drug addictions.
130 ; AOR, 1.96 [95% CI, 1.16-3.30]); history of drug addiction (4.5% stillbirths, 2.1% live births) (vs
131 ent (beta-estimate = 17.9; P = 0.004) and of drug addiction absence (beta estimate = 14.6; P = 0.049)
132 ally based sex differences in every phase of drug addiction: acute reinforcing effects, transition fr
133 of reward neural circuitry, but I argue that drug addiction also involves another major source of rei
134 the enormous societal burden of alcohol and drug addiction and abundant research describing drug-ind
138 pation and dysregulation of these systems in drug addiction and evaluates the current understanding o
139 exhibits symptomatology that mimics that of drug addiction and is hypothesized to be due to dysregul
140 itical to the acquisition and maintenance of drug addiction and is modulated strongly by nicotine act
150 and their potential therapeutic benefits in drug addiction and other neuropsychiatric changes in rew
151 been considered as potential medications for drug addiction and other neuropsychiatric disorders.
152 motional/motivational alterations related to drug addiction and other psychiatric disorders, and thes
155 studied for its association in a variety of drug addiction and pain sensitivity phenotypes; however,
162 Since epigenetic changes are implicated in drug addiction and tolerance phenomenon, this study coul
164 evelopment of pharmacological treatments for drug addiction and, more generally, further our understa
165 reported among individuals with alcohol and drug addictions and contribute to the acquisition and ma
167 one of the primary behavioral components of drug addiction, and cue-elicited craving is an especiall
168 rst time this impaired insight hypothesis in drug addiction, and examined its potential association w
169 would someday lead to better treatments for drug addiction, and he would be gratified to know that s
170 mily of KCNN genes in alcohol, nicotine, and drug addiction, and identify KCNN3 as a mediator of volu
173 role in the motivational systems underlying drug addiction, and recent work has suggested that they
174 ranging from depression to eating disorders, drug addiction, and related compulsive pursuits of rewar
176 of plasticity that control vulnerability to drug addiction, and that this increased vulnerability is
177 triatal function in models of depression and drug addiction, and thus we hypothesized that dorsal str
179 licated in several disease states, including drug addiction, anxiety, depression, obesity, and chroni
182 We and others showed previously that cancer drug addiction arises also in the hematologic malignancy
183 ment of neuropsychiatric disorders including drug addiction, as well as prefrontal cortical refinemen
184 een postulated as a behavioral treatment for drug addiction based on its preventive effects in animal
185 cal gamblers in core circuitry implicated in drug addiction, but also highlights some subtle differen
188 y induced by drugs of abuse for behaviors of drug addiction, but GluA1 roles in emotional learning an
189 retin/orexin system plays a critical role in drug addiction, but the potential participation of this
191 the possibility of developing therapies for drug addiction by targeting ASIC-dependent neurotransmis
195 ransition from casual drug use to compulsive drug addiction could aid in the development of treatment
196 physiology of several human diseases such as drug addiction, depression, neurodegenerative disorders,
199 chanisms that underlie the predisposition to drug addiction from effects of drugs in adolescents.
203 These observations echo two core features of drug addiction: high motivation to seek addictive substa
204 striatum is important for the development of drug addiction; however, a precise understanding of the
205 h as obsessive-compulsive disorder (OCD) and drug addiction; however, additional work is needed to ad
206 tion of the brain's reward circuitry seen in drug addiction; however, the specific genes regulated an
207 l for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of s
215 psychiatric disorders, from schizophrenia to drug addiction, involve abnormalities in both the mesoli
230 ward-related behavior.SIGNIFICANCE STATEMENT Drug addiction is a widespread public health concern oft
240 s addicted, but the likelihood of developing drug addiction is greater in people with a family histor
241 ggest treating the stress-related aspects of drug addiction is likely to be an important contributing
246 Importance: A common trigger for relapse in drug addiction is the experience of craving via exposure
253 as aimed to outline the neural mechanisms of drug addiction, it has overwhelmingly focused on male su
255 in NAc function similar to those underlying drug addiction may contribute to obesity, particularly i
256 merging evidence suggesting that obesity and drug addiction may share common hedonic mechanisms will
257 in midbrain dopaminergic regions involved in drug addiction, mental illness, and movement control in
258 using the theoretical framework of prominent drug addiction models, investigating the neurobiological
259 itters in the control of energy homeostasis, drug addiction, mood and motivation, sleep-wake states,
260 mine D2 receptor (D2R) and are implicated in drug addiction, movement disorders, and nociception.
262 nd its activator p35 have been implicated in drug addiction, neurodegenerative diseases such as Alzhe
263 d role of glutamatergic neurotransmission in drug addiction, novel medication development strategies
264 ders of the CNS, including schizophrenia and drug addiction, our findings have substantial clinical r
265 s been widely studied for its association in drug addiction, pain sensitivity, and, more recently, so
269 t not those to BRAFi alone, displayed robust drug addiction, providing a potentially exploitable ther
272 g opiate methadone is commonly used to treat drug addiction, relatively little is known about the eff
276 While the role of NAc FSIs in the context of drug addiction remains poorly understood, emerging evide
282 8A haplotypes with eQTL SNPs associated with drug addiction (rs510769) and obesity (rs9478496) in pop
283 myriad neuropsychiatric disorders, including drug addiction, schizophrenia, depression, epilepsy, and
286 s both with and without clinically diagnosed drug addiction, siblings of addicted individuals, and co
287 ing of impulsivity-related disorders such as drug addiction.SIGNIFICANCE STATEMENT The claustrum is o
288 jections, are often used as a model to study drug addiction, similar effects have been difficult to d
290 addictions share many clinical features with drug addictions, they show strikingly large variation in
291 he future treatment of relapse prevention in drug addiction through memory reconsolidation blockade.
292 Here we used established rodent models of drug addiction to determine whether they would be sensit
294 ic research on neurobiological mechanisms of drug addiction, treatment options remain largely unchang
296 n is postulated to increase vulnerability to drug addiction-was impaired in both adolescent mice and
298 he striatum is involved in the mechanisms of drug addiction, we studied how the transgene affected st
300 postulated to play key roles in alcohol and drug addiction; yet, to date, little is understood regar